Stock Forecast

  IRIDEX Corporation ( IRIX) Stock. Should you Buy or Sell?    $ 2.56

0.04 (1.54 %)



IRIDEX Corporation Analysis

Updated on 10-09-2022
Symbol IRIX
Price $2.56
Beta 1.316
Volume Avg. $44.89 thousand
Market Cap $40.92 M
52 Week Range $2.4 - $9.46


IRIDEX Corporation opened the day at $2.56 which is +'1.54 % on yesterday's close. IRIDEX Corporation has a 52 week high of $9.46 and 52 week low of $2.4, which is a difference of $7.06. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $40.92 M and total net profit is $53903000 which means the company is trading at 0.76 times profit to market capitalization. Theoretically, if you were to buy IRIDEX Corporation for $40.92 M, it would take 15 years to get your money back. IRIDEX Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




IRIDEX Corporation Stock Forecast - Is IRIDEX Corporation a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreBuy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -4.404
Dividend Yiel 0.000
Net Profit Margin -0.319


Valuing IRIDEX Corporation


Price Book Value Ratio 2.094 Price To Book Ratio 2.094
Price To Sales Ratio 1.405 Price Earnings Ratio -4.404


How liquid is IRIDEX Corporation


Current Ratio 3.193
Quick Ratio 2.006


Debt


Debt Ratio 0.574 Debt Equity Ratio 1.349
Long Term Debt To Capitalization 0.059 Total Debt To Capitalization 0.102



Latest news about IRIDEX Corporation


IRIDEX (IRIX) Stock: Why It Fell 8.58%

The stock price of IRIDEX (IRIX) fell by 8.58% in the previous trading session. This is why.

Date : 27/08/2022

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 1:00 p.m. Pacific time / 4:00 p.m. Eastern time.

Date : 18/08/2022

IRIDEX Corporation's (IRIX) CEO David Bruce on Q2 2022 Results - Earnings Call Transcript

IRIDEX Corporation (NASDAQ:IRIX ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Leigh Salvo - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Scott Henry - ROTH Capital Operator Good day and thank you for standing by. Welcome to the IRIDEX Second Quarter 2022 Earnings Conference Call.

Date : 15/08/2022

Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates

Iridex (IRIX) delivered earnings and revenue surprises of 12.50% and 1.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 15/08/2022

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022

MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022 after the close of trading on Monday, August 15, 2022. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.

Date : 01/08/2022





About IRIDEX Corporation


CEO : Mr. David Bruce
Sector : Healthcare
Industry : Medical Devices

Website : https://www.iridex.com

Exchange : NASDAQ Global Market

Description :

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.


My Newsletter

Sign Up For Updates & Newsletters